Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Elucidating extrachromosomal DNA-borne drivers of glioblastoma

FY 2025-26

Summary
Glioblastoma (GBM) is a fast-growing brain cancer with few effective treatments and a poor prognosis. Many GBM tumours develop extra circular fragments of DNA, termed extrachromosomal DNA (ecDNA), which exist alongside chromosomes in the nucleus. The presence of ecDNA in GBM tumours is associated with cancer progression and lethality. These ecDNA molecules often carry genes known to drive tumour growth, yet most genes found on GBM-derived ecDNA have no known link to cancer. Amongst these genes may be drivers of cancer that are yet to be elucidated, representing novel clinical targets that, once uncovered, can be leveraged to advance GBM survivorship. To investigate this possibility, I will coalesce sequencing data from hundreds of patient samples to create the largest dataset of GBM-derived ecDNA to date. After identifying all genes that occur on these ecDNAs, I will use CRISPR activation (CRISPRa) to induce the expression of these genes in the brain of an established GBM mouse model and in human GBM cells. Activated genes that cause tumour formation in mice or overgrowth in human cells will represent GBM drivers of interest and will be revealed by sequencing. The use of a GBM mouse model will enable the identification of biologically relevant cancer driver genes that can only be elucidated in complex tissue environments, while human cell lines will validate the clinical relevance of these genes. These complementary approaches will produce a list of ecDNA-borne genes that drive GBM growth, including both known cancer genes and newly uncovered drivers that can be investigated for therapeutic potential. Ultimately, this work will inform the development of personalized and specific gene-targeted treatments to combat the aggressively lethal nature of this disease.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572820
Name
Juba Jade J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating extrachromosomal DNA-borne drivers of glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Crispr Activation; Extrachromosomal Dna; Glioblastoma; In Vivo Crispr Screening
Abstract
Glioblastoma (GBM) is a fast-growing brain cancer with few effective treatments and a poor prognosis. Many GBM tumours develop extra circular fragments of DNA, termed extrachromosomal DNA (ecDNA), which exist alongside chromosomes in the nucleus. The presence of ecDNA in GBM tumours is associated with cancer progression and lethality. These ecDNA molecules often carry genes known to drive tumour growth, yet most genes found on GBM-derived ecDNA have no known link to cancer. Amongst these genes may be drivers of cancer that are yet to be elucidated, representing novel clinical targets that, once uncovered, can be leveraged to advance GBM survivorship. To investigate this possibility, I will coalesce sequencing data from hundreds of patient samples to create the largest dataset of GBM-derived ecDNA to date. After identifying all genes that occur on these ecDNAs, I will use CRISPR activation (CRISPRa) to induce the expression of these genes in the brain of an established GBM mouse model and in human GBM cells. Activated genes that cause tumour formation in mice or overgrowth in human cells will represent GBM drivers of interest and will be revealed by sequencing. The use of a GBM mouse model will enable the identification of biologically relevant cancer driver genes that can only be elucidated in complex tissue environments, while human cell lines will validate the clinical relevance of these genes. These complementary approaches will produce a list of ecDNA-borne genes that drive GBM growth, including both known cancer genes and newly uncovered drivers that can be investigated for therapeutic potential. Ultimately, this work will inform the development of personalized and specific gene-targeted treatments to combat the aggressively lethal nature of this disease.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Juba, Jade J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~